Patents
Literature
6 results about "Ionotropic receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Ionotropic receptors form an ion channel pore. In contrast, metabotropic receptors are indirectly linked with ion channels on the plasma membrane of the cell through signal transduction mechanisms, often G proteins. Hence, G protein-coupled receptors are inherently metabotropic.
Fused heterocyclic derivatives as negative allosteric modulators of mglu7 receptor
The present invention relates to novel compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.
Owner:NEUROSTERIX PHARMA SÀRL
NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS
The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The application is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.
![NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS](https://images-eureka.patsnap.com/patent_img/4e0cf8e5-3fba-43e3-8151-d29a3a8f8ec5/US20260184715A1-C00001.png "NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS")
![NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS](https://images-eureka.patsnap.com/patent_img/4e0cf8e5-3fba-43e3-8151-d29a3a8f8ec5/US20260184715A1-C00002.png "NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS")
![NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS](https://images-eureka.patsnap.com/patent_img/4e0cf8e5-3fba-43e3-8151-d29a3a8f8ec5/US20260184715A1-C00003.png "NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS")
Owner:ADDEX PHARMACEUTICALS SA
Novel pyrrolo[1,2-d][1,2,4]triazinone derivatives as negative allosteric modulators of the MGLU7 receptor
TIFF2025538048000094.tif34115 The present invention relates to novel compounds of formula (I), wherein P, Q, A, B, m, n, R 1 , R 2 and R 3 are defined as in Formula (I); which are negative allosteric modulators of metabotropic glutamate receptor subtype 7 (mGlu7) and are useful for treating or preventing neurological, otic, and psychiatric disorders associated with glutamate dysfunction, and disorders involving the mGlu7 subtype of metabotropic receptor. The present invention is also directed to pharmaceutical compositions comprising such compounds, processes for preparing such compounds and such compositions, and the use of such compounds for the prevention or treatment of neurological, otic, and psychiatric disorders involving mGlu7.
![Novel pyrrolo[1,2-d][1,2,4]triazinone derivatives as negative allosteric modulators of the MGLU7 receptor](https://images-eureka.patsnap.com/patent_img/4ecc67c4-9d7b-4c5d-9e8e-40de2d99f054/2025538048000001.png "Novel pyrrolo[1,2-d][1,2,4]triazinone derivatives as negative allosteric modulators of the MGLU7 receptor")
Owner:NEUROSTERIX PHARMA SÀRL
Use of stem cell-based biosensors for real-time, non-invasive monitoring of neuronal differentiation
PendingUS20260036580A1Polypeptide with localisation/targeting motifCell receptors/surface-antigens/surface-determinantsInteinFluorescent protein
Compositions and methods for real-time non-invasive monitoring of neuronal differentiation. Biosensor proteins comprising N-fusion and C-fusion proteins the express Adaptor Protein Complex 2 (AP2) and glutamate ionotropic receptor AMPA type subunit 2 (GRIA2), respectively, as well as split inteins and a reporter molecule enable the detection of hippocalcin via the translocation of a fluorescent protein into the nucleus of a cell.
Owner:RUTGERS THE STATE UNIV +1
Novel pyrrolo[1,2-d][1,2,4]triazin-1-one derivatives as negative allosteric modulators of the MGLU7 receptor
TIFF2025538049000047.tif38119 The present invention relates to novel compounds of formula (I), wherein P, Q, A, B, m, n, R 1 , R 2 and R 3 are defined as in Formula (I); which are negative allosteric modulators of metabotropic glutamate receptor subtype 7 (mGlu7) and are useful for treating or preventing neurological, otic, and psychiatric disorders associated with glutamate dysfunction, and disorders involving the mGlu7 subtype of metabotropic receptor. The present invention is also directed to pharmaceutical compositions comprising such compounds, processes for preparing such compounds and such compositions, and the use of such compounds for the prevention or treatment of neurological, otic, and psychiatric disorders involving mGlu7.
![Novel pyrrolo[1,2-d][1,2,4]triazin-1-one derivatives as negative allosteric modulators of the MGLU7 receptor](https://images-eureka.patsnap.com/patent_img/c98fb947-6fba-4bb6-8f9b-b77d6b4eb798/2025538049000001.png "Novel pyrrolo[1,2-d][1,2,4]triazin-1-one derivatives as negative allosteric modulators of the MGLU7 receptor")
Owner:NEUROSTERIX PHARMA SÀRL
Novel bicyclic [1,2,4]triazolone derivatives as negative allosteric modulators of the MGLU7 receptor
TIFF2025538047000051.tif32114 The present invention relates to novel compounds of formula (I), wherein P, Q, A, B, m, n and R 1 are defined as in Formula (I); which are negative allosteric modulators of metabotropic glutamate receptor subtype 7 (mGlu7) and are useful for treating or preventing neurological, otic, and psychiatric disorders associated with glutamate dysfunction, and disorders involving the mGlu7 subtype of metabotropic receptor. The present invention is also directed to pharmaceutical compositions comprising such compounds, processes for preparing such compounds and such compositions, and the use of such compounds for the prevention or treatment of neurological, otic, and psychiatric disorders involving mGlu7.
![Novel bicyclic [1,2,4]triazolone derivatives as negative allosteric modulators of the MGLU7 receptor](https://images-eureka.patsnap.com/patent_img/d8638646-4e0f-4ba3-9024-d5cb4bc5ae6a/2025538047000001.png "Novel bicyclic [1,2,4]triazolone derivatives as negative allosteric modulators of the MGLU7 receptor")
Owner:NEUROSTERIX PHARMA SÀRL